Durvalumab after chemoradiotherapy improves survival in limited-stage SCLC

Osimertinib success in locally advanced EGFR-mutated NSCLC

Adagrasib improves on docetaxel in previously treated NSCLC

Maintenance systemic therapy versus local consolidative therapy plus maintenance systemic therapy for NSCLC

Telehealth delivery of palliative care an effective alternative to in-person visits for patients with advanced lung cancer

Ivonescimab benefit for EGFR mutant NSCLC patients who failed TKI therapy

Blood tumour mutational burden and response to pembrolizumab plus chemotherapy in non-small cell lung cancer

Avelumab plus platinum-based chemotherapy may show some efficacy in patients with extensive-stage small cell lung cancer

Avelumab combined with regorafenib shows improved outcome in solid tumours with tertiary lymphoid structures

Blood test may identify patients with non-small cell lung cancer subtype who can benefit from combination therapy

Concurrent low-dose radiation and durvalumab and etoposide/platinum shows promising efficacy in 1L ES-SCLC

Twice-daily chemoradiation remains the standard of care in limited stage small-cell lung cancer